- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Empagliflozin superior to DPP-4 inhibitors, GLP-1 RAs for reducing heart failure hospitalizations: EMPRISE trial
USA: The initiation of empagliflozin versus a DPP-4 inhibitor in clinical practice is associated with a relative risk reduction for heart failure hospitalization (HHF) greater than 50%, findings from the EMPRISE trial have revealed. And empagliflozin initiation versus GLP-1 receptor agonists was associated with a greater than 30% reduction in HHF.
The study findings were presented at the American Diabetes Association (ADA) 82nd Scientific Sessions and subsequently published in the journal Diabetes, Obesity and Metabolism.
"Empagliflozin initiation versus DPP-4 inhibitor is associated with a lower risk of HHF, all-cause mortality (ACM), and myocardial infarction (MI)/stroke/ACM, a similar risk of MI/stroke, and a safety profile consistent with documented information," Elisabetta Patorno, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA, and colleagues wrote in their study.
The study was conducted with the objective to investigate safety and effectiveness outcomes among patients with type 2 diabetes (T2D) initiating empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitor treatment across the broad spectrum of cardiovascular risk in a population-based cohort study.
The researchers used data from 2 US commercial insurance databases and Medicare between August 2014 and September 2017 to identify 39 072 pairs of 1:1 propensity score-matched adult patients with T2D initiating empagliflozin or DPP-4 inhibitors.
A composite myocardial infarction /stroke, and hospitalization for heart failure was the primary outcome. Safety outcomes included lower-limb amputations (LLAs), bone fractures, acute kidney injury (AKI), and diabetic ketoacidosis (DKA).
The study led to the following findings:
- Study participants had a mean age of 60 years and only 28% had established cardiovascular disease.
- Compared to DPP-4 inhibitors, empagliflozin was associated with a similar risk of MI/stroke (HR 0.99), and a lower risk of HHF (HR 0.48 and 0.63, based on a primary and any heart failure discharge diagnosis, respectively).
- The HR was 0.52 for all-cause mortality (ACM) and 0.83 for a composite of MI/stroke/ACM.
- Empagliflozin was associated with a similar risk of LLA and fractures, an increased risk of DKA (HR 1.71), and a decreased risk of AKI (HR 0.60).
"The study underlines the magnitude of impact use of SGLT2 inhibitors can provide compared with other glucose-lowering therapies," wrote the authors.
Reference:
Patorno E, Pawar A, Wexler DJ, Glynn RJ, Bessette LG, Paik JM, Najafzadeh M, Brodovicz KG, Déruaz-Luyet A, Schneeweiss S. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Obes Metab. 2022 Mar;24(3):442-454. doi: 10.1111/dom.14593. Epub 2021 Dec 1. PMID: 34729891; PMCID: PMC8939295.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751